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Abstract
Background: Dengue and other arboviruses transmitted by Aedes aegypti mosquitoes, including Zika and
chikungunya, present an increasing public health challenge in tropical regions. Current vector control strategies
have failed to curb disease transmission, but continue to be employed despite the absence of robust evidence for
their effectiveness or optimal implementation. The World Mosquito Program has developed a novel approach to
arbovirus control using Ae. aegypti stably transfected with Wolbachia bacterium, with a significantly reduced ability
to transmit dengue, Zika and chikungunya in laboratory experiments. Modelling predicts this will translate to local
elimination of dengue in most epidemiological settings. This study protocol describes the first trial to measure the
efficacy of Wolbachia in reducing dengue virus transmission in the field.
Methods/design: The study is a parallel, two-arm, non-blinded cluster randomised controlled trial conducted in a
single site in Yogyakarta, Indonesia. The aim is to determine whether large-scale deployment of Wolbachia-infected Ae.
aegypti mosquitoes leads to a measurable reduction in dengue incidence in treated versus untreated areas. The primary
endpoint is symptomatic, virologically confirmed dengue virus infection of any severity. The 26 km2 study area was
subdivided into 24 contiguous clusters, allocated randomly 1:1 to receive Wolbachia deployments or no intervention. We
use a novel epidemiological study design, the cluster-randomised test-negative design trial, in which dengue cases and
arbovirus-negative controls are sampled concurrently from among febrile patients presenting to a network of primary
care clinics, with case or control status classified retrospectively based on the results of laboratory diagnostic testing.
Efficacy is estimated from the odds ratio of Wolbachia exposure distribution (probability of living in a Wolbachia-treated
area) among virologically confirmed dengue cases compared to test-negative controls. A secondary per-protocol analysis
allows for individual Wolbachia exposure levels to be assessed to account for movements outside the cluster and the
heterogeneity in local Wolbachia prevalence among treated clusters.
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Discussion: The findings from this study will provide the first experimental evidence for the efficacy of Wolbachia in
reducing dengue incidence. Together with observational evidence that is accumulating from pragmatic deployments of
Wolbachia in other field sites, this will provide valuable data to estimate the effectiveness of this novel approach to arbovirus
control, inform future cost-effectiveness estimates, and guide plans for large-scale deployments in other endemic settings.
Trial registration: ClinicalTrials.gov, identifier: NCT03055585. Registered on 14 February 2017.
Keywords: Wolbachia, dengue, chikungunya, Zika, vector-borne disease, cluster randomised trial, test-negative design,
Indonesia
Background
The health and economic impacts of arboviral diseases
transmitted primarily by Aedes aegypti mosquitoes are
escalating globally. In 2013, the estimated annual global
burden of dengue was approximately 50–100 million
clinically apparent dengue cases [1, 2] and approximately
10,000 deaths [2]. The burden of dengue has a cost of
approximately $2.1 billion per year in the Americas [3]
and almost $1 billion per year in Southeast Asia [4, 5].
Another epidemic arbovirus, the chikungunya virus
(CHIKV), came to global attention in 2004 when it
caused epidemics on several Indian Ocean islands before
spreading to southern Europe and South and South East
Asia. Like dengue, chikungunya is a febrile systemic viral
illness of 4–7 days duration. Debilitating polyarthralgia
can be a long-lasting sequelae of CHIKV infection [6].
In 2013, CHIKV emerged again in the Caribbean and
caused epidemics in Latin American countries that are
ongoing [7]. There are no licensed vaccines or specific
therapies for chikungunya. Against this backdrop of en-
demic or epidemic dengue in over 100 countries, and re-
cent explosive outbreaks of chikungunya, the Zika virus
emerged in epidemic fashion in the Western Pacific in
2013 and in Latin America in 2015 [8]. As evidence ac-
cumulated that it causes congenital infections with se-
vere outcomes, including fetal death and severe
microcephaly, it was declared a public health emergency
of international concern by the World Health
Organization (WHO) [9]. Like chikungunya, there are
no licensed vaccines or specific therapies for Zika.
Vector control targeted against Ae. aegypti is the
mainstay of the fight against dengue, chikungunya and
Zika disease transmission in endemic countries. Inte-
grated control strategies include targeted residual spray-
ing, space spraying, larval control and personal
protection measures. However, successful broad-scale
application of integrated vector control has been espe-
cially difficult to achieve in resource-limited endemic
countries and impossible to sustain. Additionally, the
evidence base to prioritise one intervention over another
(e.g. larvicides and outdoor versus indoor insecticide
space spraying) is weak as none have been robustly eval-
uated for impact on human infection and disease [10,
11]. Indeed, a recent meta-analysis of entomological
intervention trials highlighted the paucity of reliable evi-
dence for the effectiveness of any vector control method
on dengue incidence [12]. Strikingly, none of the rando-
mised controlled trials of vector control that were in-
cluded in the meta-analysis investigated epidemiological
impact (i.e. clinical disease endpoint) [12]. The difficulty
of making evidence-based policy in relation to vector
control has resulted in calls for improved trial methods
[13].
The World Mosquito Program (formerly Eliminate
Dengue Program) is an international research collabor-
ation aiming to use Wolbachia to eliminate arboviral
disease transmission by Ae. aegypti mosquitoes [14]. The
presence of Wolbachia in Ae. aegypti mosquitoes ren-
ders them more resistant to disseminated arbovirus in-
fection, including dengue, Zika, chikungunya and yellow
fever viruses [15–17]. Thus, the critical and signature ef-
fect of Wolbachia as a public health intervention is to
severely reduce the vectorial capacity of mosquito popu-
lations to transmit arboviral infections between humans.
For field implementation, the approach works by seeding
wild Ae. aegypti populations with Wolbachia via fort-
nightly releases, over a period of 2–3 months, of rela-
tively small numbers of Wolbachia-infected mosquitoes.
Over the subsequent 3–6 months, and through the ac-
tions of cytoplasmic incompatibility, the prevalence of
Wolbachia in the local mosquito population increases,
until such time as virtually all mosquitoes in the area
carry Wolbachia [18]. Once established, Wolbachia sus-
tains itself in the mosquito population for years. Of note,
when Wolbachia is stably established in mosquito popu-
lations, there is predicted to be a 66–75% reduction in
the basic reproduction number R0 for dengue viruses
(DENV)-1 to -4 [19]. Reductions of this magnitude are
predicted to result in local elimination of DENV trans-
mission in most epidemiological circumstances [19].
With a population of approximately 250 million,
Indonesia is the largest dengue endemic country in
South East Asia. The administrative area of Yogyakarta
City, in south-central Java, with a population of 414,000
(in 2016) in an area of 32 km2 [20], has generally had a
higher dengue incidence than surrounding districts [21].
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Between 2006 and 2016 the local public health surveil-
lance system in Yogyakarta City received notification of
9418 hospitalised dengue cases, including large out-
breaks in 2010 and 2016.
Small-scale proof-of-concept field trials of Wolbachia
(wMel strain) deployment have been successfully con-
ducted in four small communities in districts adjacent to
Yogyakarta City since 2014 (unpublished). The study
protocol presented here represents the first cluster ran-
domised trial to experimentally measure the efficacy of
Wolbachia in reducing DENV transmission.
Methods/Design
The aim of this study is to determine whether
large-scale deployment of Wolbachia-infected Ae.
aegypti mosquitoes leads to a measurable reduction in
dengue incidence in people living in treated (interven-
tion) areas, compared to those in untreated areas. The
primary endpoint is symptomatic, virologically con-
firmed DENV infection of any severity. Secondary objec-
tives are the measurement of the efficacy of the
Wolbachia method in reducing the incidence of symp-
tomatic, virologically confirmed Zika virus (ZIKV) or
CHIKV infection of any severity in treated areas, relative
to untreated areas; quantification of the level of human
mobility within Yogyakarta City and estimation of the
proportion of time that residents spend outside the
treatment arm to which they were randomised; and
measurement of the impact of Wolbachia deployment
on the prevalence of arbovirus-infected Ae. aegypti
mosquitoes.
Study design
The study is a parallel, two-arm, non-blinded cluster
randomised controlled trial conducted in a single site in
Yogyakarta, Indonesia. The study area was subdivided
into 24 contiguous clusters of roughly equal area and
population size, which were randomly allocated in a 1:1
ratio to receive Wolbachia deployments or no interven-
tion. Additional file 1 provides an overview of the ele-
ments of the study protocol, as described in a SPIRIT
checklist.
The impact of Wolbachia deployments on dengue in-
cidence will be assessed using a novel epidemiological
study design, the cluster-randomised test-negative design
(CR-TND) trial, which is described in detail elsewhere
[22, 23]. In brief, dengue cases and arbovirus-negative
controls will be sampled concurrently from within the
population of patients presenting with undifferentiated
febrile illness to a network of primary care clinics across
the study area, with case or control status classified
retrospectively based on the results of laboratory diag-
nostic testing. Efficacy is estimated by comparing the ex-
posure distribution (probability of living in a
Wolbachia-treated area) among virologically confirmed
dengue cases against the exposure distribution in
test-negative controls. The distribution of Wolbachia ex-
posure in the sampled arbovirus-negative controls is as-
sumed to reflect the distribution of Wolbachia exposure
in the underlying source population that gave rise to
cases, as long as a core assumption is met that the rela-
tive propensity to seek healthcare for undifferentiated fe-
brile illness at a primary health clinic (known locally as
Puskesmas), in intervention versus untreated arms, is the
same for dengue cases as for other febrile illness con-
trols [23]. This should be upheld if dengue cases and
other undifferentiated febrile illness controls are clinic-
ally indistinguishable until laboratory diagnosis. The
concurrent sampling of controls and cases means that
the odds of Wolbachia-exposure among sampled dengue
cases relative to test-negative controls (odds ratio), is an
unbiased estimate of the relative incidence of medically
attended dengue in Wolbachia-treated versus untreated
clusters (risk or rate ratio (RR)), from which protective
efficacy can be directly estimated [23]. The null hypoth-
esis is that the relative incidence of virologically con-
firmed dengue in Wolbachia-treated and untreated areas
is one. If Wolbachia has a protective effect against
DENV transmission, we would expect the RR for viro-
logically confirmed dengue in Wolbachia-treated areas
compared to untreated areas to be below one.
Study setting
The study will be conducted in the adjacent districts of
Yogyakarta City and Bantul, in the province of
Yogyakarta Special Region, Indonesia. Yogyakarta City
has an area of 32 km2 and had a population of approxi-
mately 414,000 in 2016 [20]. The study site area is of 26
km2, including 24 km2 within Yogyakarta City and ex-
tending into 2 km2 of the adjacent administrative area,
Bantul District, to the south of Yogyakarta City (Fig. 1).
The study site is a continuous urban area, with a total
population of approximately 350,000 and an average
population density of 13,460 persons per km2. The an-
nual notified dengue incidence rate in Yogyakarta ranged
between 91 and 412 cases per 100,000 population during
the years 2006–2016.
The study site was subdivided into 24 contiguous clus-
ters, each with an area of approximately 1 km2 (range
0.7–1.65 km2). There are no buffer areas between clus-
ters, but natural borders (roads, rivers, non-residential
areas) were used to define cluster boundaries as much as
possible, to limit the spatial spread of Wolbachia from
treated clusters into untreated areas, and of wild-type
mosquitoes in Wolbachia-treated clusters. Exclusion
areas were minimised, and any areas within the study
site where releases are not possible for reasons of logis-
tics, public acceptance or absence of mosquito
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populations (e.g. hospitals, public space, open parkland)
were pre-specified prior to randomisation and balanced
between study arms. No attempt will be made to alter
the routine dengue prevention and vector control activ-
ities conducted by public and private agencies through-
out the study area (treated and untreated clusters).
Randomised allocation of the intervention
Among the 24 clusters, 12 were randomised to receive
Wolbachia deployments and 12 to remain untreated
(Fig. 1). Covariate constrained (‘restricted’) randomisa-
tion was used to prevent a chance imbalance in the
baseline characteristics or spatial distribution of treated
and untreated clusters, given the relatively small number
of randomisation units, using the method outlined by
Hayes and Moulton [24]. Constraining variables include
those that may be potentially confounding covariates,
may impact sample size or are relevant for logistics
(Table 1).
The covariates, data sources and cluster values in-
cluded in the constrained randomisation are summarised
in Table 1. Briefly, values for each balancing covariate
were calculated for each of the 24 clusters and across
the study area as a whole. Stata statistical software
(v13.0, StataCorp, USA) was used to generate a large
number (n = 100,000) of potential random allocations of
the 24 clusters equally into two study arms. For each al-
location, the value of each balancing criterion was calcu-
lated in each study arm in two ways, namely (1) the
average of the 12 cluster-level values and (2) the
Fig. 1 Map of Applying Wolbachia to Eliminate Dengue (AWED) trial study site. The study site is a continuous area of 26 km2, including 24 km2
in Yogyakarta City and 2 km2 in adjacent Bantul Regency, to the south. Nineteen government primary healthcare clinics (Puskesmas) where
recruitment of febrile participants will take place are shown
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aggregate arm-level value. Each potential random alloca-
tion was evaluated against the pre-defined balancing cri-
teria (Table 1), and rejected if they were not met. All
potential allocations that satisfied the balancing criteria
were retained (n = 247), and a single allocation was then
randomly selected from within the restricted list of bal-
anced allocations. Finally, a coin toss was used to deter-
mine which of the two study arms (A or B) was to
receive Wolbachia releases. There were thus 494 pos-
sible distinct intervention allocations, exceeding the
guideline threshold of 100–150 allocations suggested by
others [24–26] and shown in extensive simulations to
achieve excellent performance in terms of confidence
interval coverage [22]. The set of potential constrained
randomisations was examined to assess how frequently a
pair of clusters appeared in the same arm, and the pair-
wise correlation in cluster-level dengue incidence over
10 years was assessed, in accordance with the validity
checks recommended by Hayes and Moulton [24]. The
two pairs that occurred most frequently in the same arm
(> 65% of potential allocations) actually had less than
typical correlation when compared to other pairs.
Randomisation was conducted in January 2017 after
completing an extensive community engagement process
and obtaining written agreement from the leaders of the
37 administrative areas (kelurahans) indicating that they
were willing to have releases occur in their area, if ran-
domly allocated. The final stages of the randomisation
process, including the selection of one allocation from a
list of 100 balanced possibilities (randomly sub-selected
from the 247 total balanced allocations) and the coin
toss to determine which arm received the intervention,
were conducted in a public forum to which community
leaders and other key stakeholders were invited to maxi-
mise transparency and acceptance of the process.
Wolbachia deployment strategy
Wolbachia-infected Ae. aegypti will be deployed by set-
ting mosquito release containers (MRCs) in residential
and non-residential properties throughout the interven-
tion clusters. An MRC is a small plastic tub containing
Ae. aegypti eggs, Tetramin food and water, placed in an
outdoor area. Adult mosquitoes emerge from small holes
in the side of the MRC, approximately 7–12 days after
the MRC is deployed. Based on previous field work, we
expect to release 30,000–150,000 adults per km2 during
each release week.
Wolbachia will be deployed through rolling releases
across intervention clusters within a 6–9 month period,
with the aim of achieving a high prevalence of Wolba-
chia in treated clusters within a maximum of 12 months
(from the start of the release). Once the cluster-level
Wolbachia prevalence in trapped Ae. aegypti reaches
60–80%, deployment will then stop in that cluster and
monitoring of Wolbachia prevalence in trapped mosqui-
toes will continue throughout the study period. There
will be no remediation with additional releases if Wolba-
chia prevalence drops below 60% in the future.
Wolbachia monitoring strategy
A network of BG-Sentinel adult mosquito traps (Bio-
Gents, Germany) will be established throughout
Table 1 Covariates included in constrained randomisation
Category Covariate Rationale Balancing criterion
Potential
confounders
1. Age: % of population
< 15 yearsa
Dengue risk is age dependent Each arm within ± 5% of overall
population value
2. 3-year average dengue
incidence ratea
Historical dengue incidence
may predict future risk
Each arm within ± 5% of overall
population value
3. Education: % completed
high schoola
Proxy for socioeconomic status
that may predict dengue risk
Each arm within ± 5% of overall
population value
Potential
sources of bias
4. Incidence of other febrile illnessf
presenting to Puskesmas clinics in
2014–2015b
Prevent chance association
between other febrile illness and
intervention
Each arm within ± 5% of overall
population value
Sample size 5. Number of clusters To maximise precision and power 12 clusters per study arm
6. Cluster populationc To maximise precision and power Each arm 45–55% of total population
Logistics 7. Total cluster area (km2)d Releases to be done over approximately
half the city
Each arm 45–55% of total area
8. Non-release area within
cluster (km2)e
To prevent an excess of non-residential
areas falling in intervention arm
Each arm 45–55% of total non-release area
9. Four spatial strata To prevent a large contiguous intervention
area
Within each spatial stratum, three clusters
per study arm
Data sources: aYogyakarta and Bantul District Health Offices; bRecords from individual primary health clinics (Puskesmas); cStatistics Indonesia (BPS), 2015;
dCalculated in ArcGIS; eCalculated in ArcGIS and Google Earth.
fOther febrile illness extracted based on ICD10 codes R50 (Fever of other and unknown origin), R50.9 (Fever, unspecified), A75.9 (Typhus fever, unspecified), A49
(staphylococcal infection, unspecified site)
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intervention clusters prior to the commencement of re-
leases, evenly spaced throughout residential areas at a
density of approximately 16 traps per km2. A BG trap
network of the same density (16 traps per km2) will be
established also in untreated clusters prior to the com-
mencement of the clinical study. BG-Sentinel traps will
be serviced weekly, with trapped mosquitoes screened
for Wolbachia at weekly, fortnightly or 4-weekly inter-
vals throughout the duration of the trial, depending on
the stage of release and establishment. Once Wolbachia
has established in treated clusters and the clinical study
has commenced, Wolbachia screening will occur
4-weekly throughout the remainder of the study period.
Trapped mosquitoes will be identified using microscopy.
Individual mosquitoes (male and female) will be tested for
Wolbachia by quantitative polymerase chain reaction
(PCR) assay. The Wolbachia prevalence in screened Ae.
aegypti will be reported aggregated to the cluster level.
For the purposes of measuring the efficacy endpoint in
the primary intention-to-treat analysis, Wolbachia will
be considered as established throughout intervention
clusters 1 month after completing releases in the last
cluster.
Study participants
Participant enrolment to measure the efficacy endpoint
will be conducted at a network of 19 Puskesmas
throughout the study site (Fig. 1). Based on 2 years of
historic data collated from the Puskesmas network in the
study area, it is estimated that at least 5000 patients per
year present to these clinics with febrile illness (range
200–1500 per clinic per annum). We will invite the par-
ticipation of all patients aged 3–45 years presenting to
any of the participating clinics with undifferentiated
fever of 1–4 days duration, who meet the eligibility cri-
teria as described in Table 2 and who provide written in-
formed consent (from a parent or guardian for
participants aged < 18 years). An individual presenting
on repeat occasions for different febrile episodes will be
eligible for enrolment during each different episode.
However, an individual may only be enrolled once
during a single illness episode, which is defined
conservatively as illness occurring within 4 weeks of a
previous febrile illness.
Data and sample collection
A unique identifier will be assigned to each participant
at enrolment. Basic demographic details, eligibility
against the inclusion criteria, illness onset date and a
10-day retrospective travel history will be recorded in a
standardised electronic data collection form. Figure 2
summarises the data and samples to be collected from
each participant. Data and samples are collected at a sin-
gle time point at enrolment, with no longitudinal
follow-up of participants except for a phone call to es-
tablish their status at 14–21 days post enrolment.
A brief travel history interview will be conducted at
enrolment to determine the main places visited by each
participant on days 3–10 prior to illness onset, i.e. dur-
ing the incubation period for dengue. Participants will
be prompted to recall the locations visited for an hour
or more at a time between 5 am and 9 pm on each day,
and the duration spent at each location, using a
tablet-based data collection tool. The coordinates of
each unique location visited will be derived by geoloca-
tion on a digital map. These data will be used to deter-
mine the proportion of time spent in Wolbachia-treated
and untreated areas, for the per-protocol analysis.
A single 3 mL venous blood sample will be collected
from all consenting participants on the day of enrol-
ment. Blood samples will be collected and transferred to
the project laboratory on the day of collection. All diag-
nostic specimens will be processed and stored on the
same day as sample receipt and plasma stored at –80 °C
until testing.
All enrolled participants will be contacted by tele-
phone 14–21 days post enrolment to ascertain their
health status, recorded categorically as recovered or
died, and whether or not they were ever hospitalised
during this illness. This is for the purpose of ascertaining
the safety endpoints (see page 22), and does not apply to
the primary or secondary outcomes of the study. For any
participant uncontactable after three attempts, the status
will be recorded as unknown. Any death of a study
Table 2 Inclusion and exclusion criteria for study enrolment
Inclusion Criteria
(Participants must meet all of the following)
Exclusion Criteria
(Participants will not be eligible for enrolment if
any of the following are identified)
Fever, either self-reported or measured at enrolment Prior enrolment in the study within the previous 4 weeks
Date of onset of fever between 1 and 4 days prior
to the day of presentation
Localising features suggestive of a specific diagnosis other
than an arboviral infection, e.g. severe diarrhoea, otitis,
pneumonia
Aged between 3 and 45 years old
Resided in the study area every night for the
10 days preceding illness onset
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participant within 14–21 days of enrolment will be clas-
sified as a serious adverse event and reported to the trial
steering committee (TSC), ethical committees and inde-
pendent data monitoring committee (IDMC) within
7 days of ascertainment. The proportion of participants
in each arm that were hospitalised or died will be
reviewed at each meeting of the IDMC.
Laboratory investigations
Reverse transcriptase quantitative PCR (RT-qPCR) is the
gold standard method of diagnosing arboviral infections in
the first few days of illness. We will use an internally con-
trolled triplex RT-qPCR assay to detect DENV, CHIKV and
Zika viruses in plasma samples from all enrolled partici-
pants (Fig. 3). Dengue non-structural protein 1 (NS1) Plate-
lia ELISA (BioRad, USA) and IgM and IgG capture ELISA
(Panbio, Australia) will be performed according to the man-
ufacturers’ instructions. These kits were selected as they
were among the best performers in a WHO evaluation of
dengue diagnostic tests [27, 28].
Diagnostic test results will not be reported back to
individual participants since batch processing of sam-
ples will mean that results are not available in time
to inform clinical management. Participants will be
managed according to standard clinical practice by
the treating clinicians.
Case and control classification
The diagnostic algorithm for classifying dengue, Zika or
chikungunya cases and arbovirus-negative controls is
shown in Fig. 3. Dengue cases are defined as patients
with virologically confirmed DENV infection, meeting
the clinical criteria for enrolment and also with a posi-
tive result in NS1 ELISA and/or DENV RT-qPCR.
Controls are patients meeting the clinical criteria for
enrolment, but with negative test results for CHIKV
RT-qPCR, Zika RT-qPCR, DENV NS1 ELISA, DENV
RT-qPCR, and DENV IgM and IgG ELISA.
For the secondary endpoints, Zika or chikungunya
cases are defined as patients with virologically confirmed
Zika virus or CHIKV infections, meeting the clinical cri-
teria for enrolment and also with a positive result in
Zika RT-qPCR or CHIKV RT-qPCR, respectively, and
controls are defined as above.
Expected study duration
Wolbachia deployments commenced in March 2017
and finished in November 2017. The clinic-based
sampling of febrile patients commenced in a pilot
phase in November 2017, with enrolment into the
intention-to-treat dataset commencing in January
2018. The study timeline is depicted in Fig. 4.
Participant enrolment will continue for 2 years, or
longer if required to attain the minimum sample
Fig. 2 Schedule of enrolment, data collection and assessments (SPIRIT Figure) *Routine dengue prevention and vector control activities will not
be altered in treated or untreated clusters
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size for intention-to-treat analysis. Recruitment will
continue for 24 months even if the estimated mini-
mum sample size is reached sooner.
Power calculations
It is estimated that approximately 1000 cases plus four
times as many controls will be sufficient to detect a 50%
reduction in dengue incidence with 80% power. The esti-
mate relies on several assumptions, outlined below.
Sample size requirements will be re-estimated using ob-
served data after 50% of the target recruitment is com-
pleted to account for possible violations to these
assumptions. This power reassessment will be based on
the actual observed distributions of test-positive (i.e.
dengue) and test-negative (i.e. other febrile illness) cases
across the 24 clusters, and will then be used to make
recommendations regarding the necessary sample size of
total dengue case counts and whether extending eligible
enrolments beyond the current protocol may be
desirable.
No formulae have previously been published to esti-
mate sample size for the proposed study design, i.e. a
cluster randomised trial with a test-negative design,
where the intervention effect is estimated from
Fig. 4 Applying Wolbachia to Eliminate Dengue (AWED) trial time line. Wol Wolbachia, IDMC Independent Data Monitoring Committee
Fig. 3 Flowchart of data and sample collection and diagnostic algorithm. Blue boxes indicate participant recruitment and enrolment activities
undertaken at Puskesmas clinics, including screening against inclusion/exclusion criteria, obtaining written informed consent, and collection of
demographic and travel history data and a blood sample. Pink boxes indicate the laboratory diagnostic testing to be performed at the project
laboratory (DU), the results of which (white boxes) will be used to classify participants as virologically confirmed dengue, Zika or chikungunya
cases, arbovirus-negative controls, or excluded due to inability to rule out arbovirus infection (grey boxes) according to the algorithm shown
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outcome-based sampling of test-positive and
test-negative patients and ascertainment of their expos-
ure status. Randomisation provides a basis of inference
in comparing intervention clusters with control clusters
as, under the null hypothesis, there should be no differ-
ence with regard to the relative appearance of test posi-
tives and negatives in clusters, on average, across the
two arms. Thus, we have proposed, as the primary ana-
lytical approach, a comparison of the exposure odds
among test-positive cases versus test-negative controls
(for data aggregated across all clusters), with the null hy-
pothesis that the odds of residence in a Wolbachia--
treated cluster is the same among test-positive cases as
test-negative controls [22, 23]. The resulting odds ratio
thus provides an estimation of the intervention effect
and, as demonstrated previously, provides an unbiased
estimate of the relative risk provided that the key as-
sumptions underlying the TND are upheld.
A secondary approach employs, as a summary meas-
ure for a group-level analysis, the proportion of
test-positive cases amongst all tested participants in each
cluster, with a comparison of the average of these pro-
portions in the intervention arm versus the untreated
arm forming the basis of hypothesis testing for interven-
tion effect. The null hypothesis is that the average pro-
portion of total enrolled participants that are cases is the
same in treated and untreated study arms. The alterna-
tive hypothesis is that the proportion of enrolled partici-
pants that are cases is lower in the Wolbachia-treated
arm than the untreated arm.
Simulations were used to estimate the power to detect
a range of intervention effect sizes using the two
methods above, assuming 12 clusters per arm, a total of
1000 true dengue cases enrolled and 4000 non-dengue
controls, and using empirical data on population, histor-
ical dengue incidence and incidence of other febrile ill-
ness in the 24 study clusters (including the observed
spatial distribution of dengue and other febrile illnesses
among clusters) to define the baseline characteristics for
the simulated scenarios [22]. We randomly allocated half
the clusters to receive the intervention; this random allo-
cation was repeated one million times, and only those al-
locations were kept in which the balancing criteria
specified in the constrained randomisation methods
were met (n = 247 balanced allocations, and thus 494
possible distinct randomisations of intervention alloca-
tion). Dengue case numbers per cluster were either kept
at baseline values (for the simulation at the null; i.e. RR
= 1) or reduced proportionately (for simulations of inter-
vention effects of RR = 0.6, 0.5, 0.4, 0.3). For each of
these five ‘true’ effect sizes, applied to each of the 247
balanced allocations, the ‘observed’ effect size was calcu-
lated from the simulated data by the two methods out-
lined above, namely (1) aggregated odds ratio for
residence in a treated cluster among cases versus con-
trols and (2) difference of the average cluster summary
proportions (cases/cases+controls) between study arms
(compared using a standard t test). Statistical inference,
from the t test directly, or, for the odds ratios, using per-
mutation distribution approximations with standard er-
rors adjusted to account appropriately for the clustered
nature of the data [22], respectively, was used to calcu-
late the proportion of constrained random allocations
that yielded a significant result. This provided an esti-
mate of Type I error at the null, and power away from
the null (Table 3). Both of these approaches thus are
using approximations to the exact permutation distribu-
tion [22]. In practice, the appropriate reference distribu-
tion for inference will be based on the set of 247
potential balanced allocations.
The results show that constrained randomisation is
somewhat conservative at the null but generally in-
creases power moderately. The odds ratio test is more
powerful than the t test approach, and will thus be used
as the primary analysis with the additional attraction of
being standard for the traditional test-negative design.
Statistical analyses
Primary endpoint – the impact of Wolbachia deployment
on dengue
The intention-to-treat (primary) analysis will consider
Wolbachia exposure as a binary classification based on
residence in a cluster allocated to Wolbachia deploy-
ment or not. Residence will be defined as the primary
place of residence during the 10 days prior to illness on-
set. The intervention effect will be estimated from an ag-
gregate odds ratio comparing the exposure odds
(residence in a Wolbachia-treated cluster) among
test-positive cases versus test-negative controls (for data
aggregated across all clusters), using the constrained per-
mutation distribution as the foundation for inference.
The null hypothesis is that the odds of residence in a
Wolbachia-treated cluster are the same among
test-positive cases as among test-negative controls. The
resulting odds ratio provides an unbiased estimate of the
RR provided that the key assumptions underlying the
TND are upheld. Of note, since the constrained
Table 3 Percentage of random allocations that yield significant
results on simulated data (i.e. power)
Risk
ratio
t test Odds ratio test
Constrained Random Constrained Random
1 0.13 5 1 7
0.6 48 49 61 57
0.5 81 75 89 82
0.4 97 93 99 96
0.3 100 99 100 100
Anders et al. Trials  (2018) 19:302 Page 9 of 16
permutation distribution used for statistical inference
contains only the 247 potential allocations (494 distinct
randomisations) that meet all balancing criteria, the
most extreme odds ratio in the distribution would carry
a two-sided p value of approximately 0.004 (2/494).
Therefore p < 0.004 is the minimum threshold at which
statistical significance can be evaluated in this design.
A secondary group-level analysis will be performed
using a cluster-level summary measure of the proportion
of test-positive individuals amongst all tested individuals
in each cluster. The difference in the average proportion
of test positives between the intervention clusters and
untreated clusters will be used to test the null hypothesis
of no intervention effect using the t test statistic but bas-
ing inference on the exact permutation distribution.
These average proportions in each arm can be used to
derive an estimate of the RR of dengue in treated versus
untreated clusters, which is a more intuitive effect meas-
ure [22]. Briefly, we can substitute the estimated differ-
ence in the proportions, d, into the formula:
d ¼ 1
1þ r
2
 
1þ RRð Þ
−
RR
RRþ r
2
 
1þ RRð Þ
where r is the overall ratio of test negatives to test pos-
itives, which yields a quadratic equation for the un-
known RR. Only one solution is plausible so that this
then yields an estimate of RR, along with the appropri-
ately transformed confidence interval (from that associ-
ated with d).
The per-protocol analysis will consider Wolbachia ex-
posure as a quantitative index based on measured Wol-
bachia prevalence in local Ae. aegypti mosquitoes in the
cluster of residence and other locations visited by the
participant during a period of 3–10 days prior to illness
onset, as reported in the travel history interview. A
weighted ‘Wolbachia exposure index’ (WEI) will be de-
fined for each participant, as follows. The aggregate Wol-
bachia prevalence for each cluster will be calculated
each month from all Ae. aegypti trapped in that cluster.
The WEI for each participant will then be calculated by
multiplying the cluster-level Wolbachia prevalence (in
the month of participant enrolment) at each of the loca-
tions visited, by the proportion of time spent at each lo-
cation, to give a value on a continuous scale from 0 to 1.
Cases and controls will be classified by strata of their
WEI (e.g. 0–0.2, 0.2–0.4, 0.4–0.6, 0.6–0.8, 0.8–1). This
acknowledges that the WEI is not a highly precise meas-
ure, and serves to reduce error in exposure classification.
The per-protocol analysis therefore allows for Wolbachia
exposure to vary in a location over time, and also ac-
counts for human mobility. This analysis can also ac-
count for the temporal matching of dengue cases and
test-negative controls, where risk sets of cases and
controls will be defined by frequency matching enrolled
confirmed dengue cases to arbovirus-negative controls
with illness onset in the same calendar month. In the
unlikely event that a minimum of four controls cannot
be found for a case within the same calendar month, the
window for matching can be extended until four con-
trols are identified, for that case only. Both inference
methods described above for the intention-to-treat ana-
lysis will be extended to allow for this individual level
covariate using regression approaches and extension of
the permutation-derived inference used to test the null
[29]. For a time-adjusted analysis, a Cox proportional
hazard model will be fitted, incorporating the temporal
risk sets using a shared frailty for cluster membership.
Such models yield an estimate, and associated confi-
dence interval, for the incidence rate ratio (the relative
hazard). The WEI strata will be included as categorical
variables to calculate stratum-specific incidence rate ra-
tios (relative to the baseline 0–0.2 stratum). This will
allow examination of a ‘dose response’ relationship. An
additional benefit of transforming WEI to a categorical
variable is that it avoids any assumption of linearity in
the dose response relationship.
The per-protocol analysis will include all participants
enrolled from the commencement of the main phase of
clinic-based sampling (i.e. excluding the pilot phase, but
including participants enrolled before Wolbachia was
established in treated clusters).
Secondary endpoint – the impact of Wolbachia deployment
on Zika and chikungunya
There exists no baseline data on the prevalence of Zika
or chikungunya infection among febrile patients present-
ing to primary healthcare clinics in Yogyakarta City from
which to estimate the expected number of cases; there-
fore, these secondary analyses are exploratory only and
not subject to any formal sample size or power calcula-
tions. Blood samples from enrolled participants will be
tested by Zika and chikungunya PCR for the purpose of
defining arbovirus-negative controls for the primary ana-
lysis, as described above. These results will permit esti-
mation of the prevalence of virologically confirmed Zika
virus and CHIKV infection among the study population
of ambulatory febrile patients presenting to primary
healthcare.
If virologically confirmed Zika or CHIKV cases are de-
tected, a secondary analysis will estimate the efficacy of
Wolbachia deployments in reducing the incidence of
symptomatic virologically confirmed Zika virus and
CHIKV infection. The same enrolled patient population
will be used to analyse all three arbovirus endpoints
(dengue, Zika and chikungunya), and the same statistical
methods for intention-to-treat and per-protocol analyses
will be used as described for the primary (dengue)
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endpoint above. For Zika and chikungunya, the cases
will be defined as enrolled participants who test positive
by Zika or chikungunya PCR, respectively, and the con-
trols will be those who test negative to all three
arboviruses.
Secondary endpoint – the impact of Wolbachia deployment
on routine dengue case notifications
The existing system for routine notification of dengue
cases in Yogyakarta City is based on hospital reporting
of cases diagnosed clinically as dengue haemorrhagic
fever, which historically have not been accompanied by
supportive laboratory testing. Since March 2016, hospi-
tals have been encouraged to record a serological testing
result, where available, on the report form, and also to
report cases diagnosed clinically as dengue fever where
there is a confirmatory NS1-positive test result. A separ-
ate reporting system, established in March 2016, collates
data on the number of NS1 rapid tests performed and
the number of positive tests, in Puskesmas across the
city.
We will collate data from these two reporting systems
on a monthly basis from 2016 to 2020, aggregated by
Kelurahan of residence, to monitor trends in reported
dengue incidence across the City and by Kelurahan, be-
fore, during and after Wolbachia deployment.
Secondary endpoint – human mobility in Yogyakarta and
implications for measuring efficacy of Wolbachia
deployment
Understanding the level and distribution of routine
movements among the study population is critical to the
success of this study design. ‘Contamination’ by human
mobility between study arms may lead to a dilution of
the true intervention effect in the intention-to-treat ana-
lysis, and will influence the degree to which the
per-protocol analysis can retain comparison groups with
different levels of Wolbachia exposure after taking into
account participants’ crude movement patterns. The data
captured through the travel history interview will be
analysed to quantify the geographical extent and dur-
ation of participants’ travel outside the home, and to es-
timate the proportion of daytime (‘at risk’) hours that
participants randomised to treated and untreated arms
actually spend in Wolbachia-treated and untreated areas,
overall and by age group. An age-stratified analysis will
describe the proportion of participants’ time (5 am to
9 pm) spent at home versus away from home, estimate
the distribution of participants’ time as a function of in-
creasing distance from home, and identify the predomin-
ant non-home locations at which participants in
different age groups spend their daytime hours. This in-
formation can inform the design of future trials of
cluster-randomised household-based interventions by
estimating the optimal size of the clusters needed to ac-
count for the majority of daily movements and providing
information on the degree to which a true intervention
effect might be diluted by movement of participants be-
tween treatment arms.
Secondary endpoint – the impact of Wolbachia deployment
on the prevalence of arbovirus-infected Ae. aegypti
mosquitoes
We will test the hypothesis that Wolbachia deployments
will reduce the prevalence of arbovirus-infected Ae.
aegypti mosquitoes. In this context, we interpret
arbovirus-infected Ae. aegypti mosquitoes as a proxy for
the presence of a viremic human host in close proximity
to the location of the infected mosquito. To test this hy-
pothesis, all Ae. aegypti mosquitoes caught in the net-
work of BG-Sentinel traps in the study area will be
tested by PCR for the presence of DENV, CHIKV and
Zika virus. Assuming a DENV infection prevalence of
0.1% in untreated clusters during the 2-year study period
2018–2019 (based on previous testing of 29,000
wild-type female Ae. aegypti in Nov 2015 to May 2016),
and assuming independence, then testing a total of
30,500 mosquitoes per arm would give 80% power to de-
tect a 60% reduction in DENV prevalence in treated
clusters (one-sided z-test; G*Power version 3.1.9.2 [30]).
Monitoring of unintended adverse effects of Wolbachia
releases
In order to demonstrate that the deployment is not asso-
ciated with any excess of a severe adverse outcome, we
will follow-up all enrolled participants (test-positive
cases and test-negative controls) by telephone 14–21 days
post enrolment to ascertain their health status, recorded
categorically as recovered/died, and whether or not they
were ever hospitalised during this illness. Any death of a
study participant within 14–21 days of enrolment will be
classified as a serious adverse event and reported to the
TSC, IDMC and the ethics committees of Universitas
Gadjah Mada and Monash University within 7 days of
ascertainment. The proportion of participants that were
hospitalised or died in each arm will be reviewed by the
IDMC each time they meet, and at any other time at the
request of the TSC or other agencies.
Data management
Data collected from participants in the clinical study will
be entered directly in standardised electronic data cap-
ture forms and digital mapping interfaces, deployed
through web-based applications on mobile devices, and
stored directly in a custom designed web-hosted rela-
tional database. Laboratory diagnostic results will be
captured directly from laboratory assay output, and
uploaded to the same database.
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In order to maintain blinding of research staff and data
managers, measures will be put in place to ensure the
datasets identifying participants’ exposure status (cluster
of residence and clusters visited during 10 days prior to
illness) will remain unlinked and partitioned from the
dataset that classifies their case/control status until the
final analysis. In the event that the IDMC requires data
to be unblinded following the interim analysis, a single
member of the World Mosquito Program, Monash Uni-
versity, data management unit will be responsible for
linking the participant dataset to the exposure status.
Role based, tiered access permissions will be used to
control access to the trial database and associated data
capture applications. User logs will document the activ-
ities of all users. Validity controls will be applied at the
point of data capture into electronic forms by predefin-
ing value ranges, specifying categorical option lists and
minimising the use of free text fields. Quality control in
the form of logic and consistency checks will be applied
at several stages of data capture and management, in-
cluding (1) at the point of data capture into an electronic
form, (2) at the point of upload into the web-based data-
base and (3) during routine monitoring processes by in-
ternal and external data monitors. An audit trail will be
preserved within the database to capture the history of
any changes made to data records after their initial cap-
ture. Data acquisition, data management and independ-
ent monitoring procedures, as well as the indefinite
retention (and for a minimum of 5 years after study
completion) of data relating to the trial, including field
entomology and epidemiological data, are in accordance
with International Council for Harmonization on Good
Clinical Practice guidelines and requirements.
Trial governance
The Principal Investigator from Universitas Gadjah
Mada, Yogyakarta, supported by the Chief Investigator
from Monash University, will be responsible for ensuring
the study is performed in compliance with the approved
protocol and the principles of Good Clinical Practice.
The TSC will provide overall supervision of the trial, in-
cluding monitoring of recruitment progress, and will con-
sider and act upon (as appropriate) any recommendation
from the IDMC with regards to early stopping of the trial.
The Trial Operations Group will, under the delegation of
the Principal Investigator, be responsible for day-to-day co-
ordination of the trial processes.
The Monitoring Group will be independent of the in-
vestigators, and will conduct periodic monitoring of ad-
herence to regulatory requirements, and implementation
of study processes including data collection and storage,
sample collection and chain of custody, and laboratory
processes.
The Data Analysis Working Group will be chaired by
the trial statistician, and will be responsible for develop-
ing the statistical methods for randomisation, data clean-
ing and validation, and preparing and implementing the
statistical analyses.
An IDMC will be constituted from local and inter-
national experts in accordance with standard practice
for randomised clinical trials. The IDMC will meet at
study initiation, 6 months following the commencement
of clinic-based enrolment, and at 50% enrolment of the
estimated minimum required number of dengue cases
(n = 500), as well as any other time at the request of the
TSC or other agencies. Their primary role is to safe-
guard the interests of the trial participants, to assess the
safety and efficacy of the intervention during the trial,
and to monitor the overall conduct of the trial.
The IDMC will provide recommendations about stop-
ping or continuing the trial, and may also make recom-
mendations relating to trial procedures, and data
management and quality control. Any proposed major
modifications to the study protocol will be reviewed by
the IDMC, and approval for a protocol amendment will
be sought from the relevant institutional review boards
(IRBs) prior to their implementation. Detailed responsi-
bilities and terms of reference will be set out in an
IDMC charter and agreed to by all IDMC members
prior to study commencement.
Interim analyses and stopping rules
An interim analysis of the primary endpoint (intention--
to-treat analysis only, using the odds ratio approach
based on the permutation distribution and blinded to
treated and untreated study arms) will be conducted by
the trial statistician when enrolment reaches 50% of the
estimated minimum required number of dengue cases
(n = 500).
The IDMC may recommend modification or ter-
mination of the study if analyses of data from the
first 50% of the estimated minimum required num-
ber of dengue cases indicate beyond reasonable
doubt that exposure to Wolbachia confers a re-
duced risk of dengue in the intention-to-treat ana-
lysis. As detailed in the analysis methods, the use
of the constrained permutation distribution for stat-
istical inference means the smallest two-sided p
value that can be observed is approximately 0.004.
The usual Haybittle–Peto boundary [31], requiring
p < 0.001 at interim analysis to consider stopping
for efficacy, cannot therefore be applied precisely.
Instead, p < 0.01 at interim analysis will be used as
guidance for considering stopping early for efficacy.
The IDMC may also recommend termination if pre-
liminary data clearly suggest that Wolbachia is as-
sociated with an excess of dengue (or Zika or
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chikungunya) cases. A less conservative p < 0.05 in
the direction of harm will be used as a guidance.
Termination or modification may also be recom-
mended for any other operational reason (e.g. par-
ticipant enrolment rates), perceived safety concern
or external factor. The final decision to terminate
or modify the study rests with the TSC.
Ethical considerations
The study protocol (version 3.0) and the informed con-
sent document have been reviewed and approved by the
IRBs of the Faculty of Medicine, Universitas Gadjah
Mada, Yogyakarta, and Monash University, Melbourne.
Any future protocol amendments will be submitted for
review and approval by the same IRBs, prior to imple-
menting protocol changes. The trial protocol was regis-
tered on ClinicalTrials.gov (NCT03055585) on 14
February 2017.
Confidentiality of participant information will be strictly
maintained at all times by the participating investigators,
research staff and the sponsoring institution (Universitas
Gadjah Mada). This confidentiality is extended to cover
testing of biological samples in addition to the clinical,
demographic and geospatial information relating to partici-
pating subjects. All laboratory specimens, reports, data col-
lection forms and log books, and geolocated records will be
identified by a coded ID number only to maintain partici-
pant confidentiality. All records that contain names or
other personal identifiers, such as informed consent forms,
will be stored separately from study records while identified
by ID numbers. All local databases will be secured with
password-protected access systems. No information con-
cerning the study or the data will be released to any un-
authorised third party, without prior written approval of
the sponsoring institution. Clinical or personal information
will not be released without written permission of the sub-
ject, except as necessary for monitoring by an ethical review
board or regulatory agencies. Reporting of study results will
not be done in any way that permits identification of indi-
vidual participants, or the location of their homes or other
visited locations.
Discussion
There exists little empirical evidence to support the effective-
ness or optimal application of the vector control tools rou-
tinely employed to combat arboviruses transmitted by Ae.
aegypti mosquitoes, including dengue, Zika and chikun-
gunya. The first dengue vaccine has recently been licensed,
but has a complex efficacy and safety profile that will con-
strain its implementation in many endemic settings. A crit-
ical need has therefore been highlighted by the scientific
community [13] and the WHO [32] for carefully designed
trials of existing and novel vector control interventions –
with epidemiological endpoints – in order to effectively
impact the transmission of dengue and other arboviruses.
This study aims to address this need, as the first trial de-
signed to measure the impact ofWolbachia-infected mosqui-
toes on dengue and other arboviral diseases in an endemic
setting.
We have employed a novel epidemiological design, the
CR-TND [22, 23], which uses outcome-based concurrent
sampling of dengue cases and non-dengue controls to
measure the efficacy endpoint. This has the potential to
be more efficient, cost effective and logistically simpler
to achieve than traditional CRT designs with prospective
cohorts. An extensive literature on the application of the
TND in (non-randomised) studies of influenza vaccine
effectiveness demonstrates the validity of effect estimates
(odds ratios) from a TND, and their equivalence to dir-
ect estimates of relative risk in the source population,
provided certain assumptions are met [33–38]; primarily,
that the distribution of test-negative illness is not associ-
ated with intervention status, and that test-negative con-
trols are allowed to include participants who may be
classified as dengue cases at other times during the
study period.
Our study uses constrained randomisation, balancing
on the historical incidence of undifferentiated febrile ill-
ness in clusters, to reduce the risk of a chance imbalance
in the distribution of test-negative controls between
study arms. However, we cannot exclude the possibility
that spatial clustering of a non-arboviral febrile illness
will result in a differential distribution of test-negative
controls between study arms during the 2-year study
period. We will assess this in the trial data by calculating
the odds of Wolbachia exposure among enrolled
test-negative controls, with the expectation that the odds
should approximate one if the assumption of no associ-
ation is upheld.
The spatial and temporal heterogeneity that is characteris-
tic of the dengue epidemiology presents a challenge to the
evaluation of dengue control interventions. At a range of
spatial scales, including within a city, there exists substantial
heterogeneity in the distribution of dengue transmission
from year to year [39–46]. This heterogeneity effectively in-
creases the baseline inter-cluster variance, and therefore re-
duces the power to detect a difference between study arms
that can confidently be attributed to Wolbachia deployment
or conversely increases the number of clusters needed to de-
tect an effect. We were limited by pre-defined boundaries of
the study site to having only 24 clusters, given the require-
ment to maintain a sufficiently minimum cluster size to en-
able Wolbachia establishment and minimise contamination
by mosquito and human movement. Nonetheless, our power
calculations have taken into account the spatial heterogeneity
observed in historical dengue and febrile illness case distribu-
tions, and indicate that adequate power is retained. We will
re-run these power calculations using real trial data once the
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trial has begun. An individual-level (per-protocol) analysis
will also account for spatial clustering of test-positive or
test-negative illness by incorporating a parameter for partici-
pants’ cluster.
Inter-annual fluctuations in dengue transmission mean
that the study might fall in a period of lower incidence
just by chance, and indeed the high dengue incidence
seen in Yogyakarta in 2016 makes this a real possibility.
However, the efficiency gains of the CR-TND make this
less of a concern than it would be for a prospective co-
hort study, and the target sample size of a minimum of
1000 dengue cases and 4000 test-negative controls is
seen as feasible even in the event of two consecutive
low-transmission seasons.
The nature of the Wolbachia intervention means that
blinding was considered infeasible, as it would have dou-
bled the resources and time required to conduct field re-
leases of mosquitoes, for example, with inactive eggs as
the placebo. The risks to study validity from a
non-blinded deployment (for example, if a belief that
Wolbachia is protective against dengue cases, residents
of treated areas may be less likely to seek care for a fe-
brile illness) were also seen to be minimised by the fact
that dengue cases and test-negative controls are drawn
from the same patient population, who are clinically in-
distinguishable at the time of presentation and enrol-
ment at clinics. Thus, the CR-TND is tolerant to the
possibility that healthcare seeking behaviour is modified
by knowledge of the Wolbachia status, as long as this
modified behaviour applies equally to test-positive den-
gue cases and test-negative controls [47].
Human movement is a challenge for cluster rando-
mised trials of community-based interventions applied
to geographic areas, because the individuals in whom
the efficacy endpoint is measured may spend some
proportion of their time outside their cluster of allo-
cation, resulting in exposure misclassification. This
has the effect of making the populations in treated
versus untreated study arms more similar to each
other in their true exposure distribution, and there-
fore biases the estimation of intervention effect to-
wards the null. We have accounted for this in two
ways. Firstly, by powering the study to detect a rela-
tively conservative effect size of 50%, we have allowed
for some dilution of effect by human movement. Sec-
ondly, by collecting travel history data from the
period immediately prior to the onset of febrile ill-
ness, we will perform an individual ‘per-protocol’ ana-
lysis in which a quantitative exposure status is
adjusted both for the time spent in clusters away
from home and the local measure of Wolbachia
prevalence in visited clusters.
Wolbachia establishment is likely to be heterogeneous
within a cluster due to spatial variation in mosquito
populations and dispersal. The classification of individ-
ual participants’ Wolbachia exposure status will there-
fore be imperfect even in the per-protocol analysis,
because Wolbachia prevalence is aggregated from all
trapped mosquitoes within one cluster in one 4-week
period (from a network of traps at a density of 16 per
km2). Because this inaccuracy is assumed to be
non-differential between clusters, the resulting exposure
misclassification should only bias the effect estimate to-
wards the null.
Extensive effort has been invested in local community
engagement leading up to this trial, extending from
community leaders and key stakeholders to the media
and the general public, with an aim of informing the
community about the planned Wolbachia releases and
addressing any concerns. Approval for releases was given
by community leaders after extensive community con-
sultation, with individual residents’ consent obtained for
hosting an MRC at their property. Community accept-
ance of the releases has remained high prior to, during
and now post-releases, and will continue to be moni-
tored throughout the duration of the trial.
We anticipate that, if the results of this trial do dem-
onstrate a reduction in dengue incidence associated with
Wolbachia deployment, this should be broadly generalis-
able to other dengue endemic settings. Any threats to
external validity of the study findings will likely relate to
the local entomological context that influences the abil-
ity of Wolbachia mosquitoes to establish and sustain,
and thus the specific approach to deployment may need
to be tailored to local contexts. The dengue-blocking
phenotype of Wolbachia is also partly serotype spe-
cific, so the local distribution of circulating DENV se-
rotypes in other settings – and also differences in
intensity of transmission – may theoretically result in
differences in observed disease impact in different set-
tings. A critical next step in translating efficacy trial
results into public health implementation of Wolba-
chia will be cost-effectiveness analyses and cost opti-
misation of different deployment scenarios, so that
the findings from this trial can be used to inform
decision-making in other settings as efficiently as
possible.
Trial status
At the time of submission, Wolbachia releases in inter-
vention clusters have finished and participant recruit-
ment in the clinical study has commenced. Pilot
recruitment commenced in November 2017, recruitment
into the intention-to-treat dataset commenced in Janu-
ary 2018, and recruitment is expected to be completed
by December 2019. The current approved protocol is
version 3.0, 13 March 2018.
Anders et al. Trials  (2018) 19:302 Page 14 of 16
Additional file
Additional file 1: SPIRIT Checklist. (PDF 197 kb)
Abbreviations
CHIKV: chikungunya virus; CR-TND: cluster randomised test-negative design;
DENV: dengue virus; IDMC: independent data monitoring committee;
IRB: institutional review board; MRC: mosquito release container; NS1: non-
structural protein 1; PCR: polymerase chain reaction; RR: risk ratio/rate ratio;
RT-qPCR: reverse transcriptase quantitative PCR; TSC: trial steering committee;
WEI: Wolbachia exposure index; WHO: World Health Organization
Acknowledgements
The authors acknowledge the contribution of Zoe Cutcher in the
development of the CR-TND methodology and the drafting of the Applying
Wolbachia to Eliminate Dengue (AWED) trial protocol; Suzanne Dufault for
performing the power simulations and contributing to the development of
the methods for statistical analysis; Peter Ryan, Immo Kleinschmidt, Christl
Donnelly and Neil Ferguson for their contributions to early discussions of trial
design; Iwan Dwiprahasto, Siswanto Agus Wilopo, Muhammad Hakimi, Hari
Kusnanto Josef and Sudijanto Kamso for their contributions to early discus-
sions of trial design; and all members of the World Mosquito Program
(WMP)-Indonesia and WMP-Global teams who have contributed to the plan-
ning and implementation of the AWED trial.
Funding
This study is funded by Yayasan Tahija (The Tahija Foundation), Indonesia.
The funders have not had a role in the design of the study, and will not be
involved in the collection, analysis or interpretation of the data.
Availability of data and materials
The full trial protocol will be made publicly available within 1 year of the
conclusion of data collection. The datasets generated in this study will be
made available by the corresponding author on reasonable request, within 1
year of the conclusion of data collection.
Authors’ contributions
KA, CI, RAA, NJ, ER, SO, CS and AU contributed to the development of the
study design. All authors contributed to the development and drafting of
the trial protocol. CI, RAA, WT, EA, BA, ER and AU are responsible for the field
implementation of the trial. NJ is the trial statistician and developed the
statistical methods for analysis. AU is the principal investigator for the trial.
KA and CS wrote the first draft of the manuscript. All authors reviewed and
approved the final manuscript.
Ethics approval and consent to participate
This trial protocol has been approved by the Universitas Gadjah Mada ethics
committee (approval number KE/FK/105/EC/2016) and Monash University
Human Research Ethics Committee (approval number 0960). Written
informed consent will be obtained from participants, or their guardian where
the participant is a minor. In addition, participants aged between 13 and
17 years will be invited to sign an assent form indicating that they
understand the research and agree to participate.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1World Mosquito Program, Institute of Vector Borne Disease, Monash
University, Melbourne, Australia. 2Department of Biostatistics, Epidemiology
and Population Health, Faculty of Medicine, Universitas Gadjah Mada,
Yogyakarta, Indonesia. 3Eliminate Dengue Project, Centre for Tropical
Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta,
Indonesia. 4Department of Pediatrics, Faculty of Medicine, Universitas Gadjah
Mada, Yogyakarta, Indonesia. 5School of Public Health, University of
California, Berkeley, USA. 6Department of Health Policy and Management,
Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Received: 13 July 2017 Accepted: 3 May 2018
References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The
global distribution and burden of dengue. Nature. 2013;496:504–7.
2. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ,
et al. The global burden of dengue: an analysis from the Global Burden of
Disease Study 2013. Lancet Infect Dis. 2016;16:712–23.
3. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact
of dengue illness in the Americas. Am J Trop Med Hyg. 2011;84:200–7.
4. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT,
et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004;22:
1275–80.
5. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of
dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7:e2055.
6. Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.
Chikungunya virus-associated long-term arthralgia: a 36-month prospective
longitudinal study. PLoS Negl Trop Dis. 2013;7:e2137.
7. Rolph MS, Foo SS, Mahalingam S. Emergent chikungunya virus and arthritis
in the Americas. Lancet Infect Dis. 2015;15:1007–8.
8. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika
virus: History, emergence, biology, and prospects for control. Antivir Res.
2016;130:69–80.
9. World Health Organization. Outcome of the Emergency Committee
Regarding Clusters of Microcephaly and Guillain-Barre Syndrome. 2016.
www.who.int/news-room/detail/01-02-2016-who-director-general-
summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-
of-microcephaly-and-guillain-barr%C3%A9-syndrome. Accessed 1 May 2017.
10. Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space
spraying with insecticide on dengue transmission; systematic review.
Tropical Med Int Health. 2010;15:619–31.
11. Pilger D, De Maesschalck M, Horstick O, San Martin JL. Dengue
outbreak response: documented effective interventions and evidence
gaps. TropIKA. 2010;1. http://journal.tropika.net/scielo.php?script=sci_
arttext&pid=S2078-86062010000100002&lng=pt&nrm=iso.
12. Bowman LR, Donegan S, McCall PJI. Dengue vector control deficient in
effectiveness or evidence?: Systematic review and meta-analysis. PLoS Negl
Trop Dis. 2016;10:e0004551.
13. Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, et al.
Evidence-based vector control? Improving the quality of vector control
trials. Trends Parasitol. 2015;31:380–90.
14. World Mosquito Program. www.worldmosquitoprogram.org. Accessed 18
May 2018.
15. Rainey SM, Shah P, Kohl A, Dietrich I. Understanding the Wolbachia-
mediated inhibition of arboviruses in mosquitoes: progress and challenges.
J Gen Virol. 2014;95:517–30.
16. Johnson KN. The impact of Wolbachia on virus infection in mosquitoes.
Viruses. 2015;7:5705–17.
17. Dutra HL, Rocha MN, Dias FB, Mansur SB, Caragata EP, Moreira LA.
Wolbachia blocks currently circulating Zika virus isolates in Brazilian Aedes
aegypti mosquitoes. Cell Host Microbe. 2016;19:771–4.
18. Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD,
McMeniman CJ, et al. The wMel Wolbachia strain blocks dengue and
invades caged Aedes aegypti populations. Nature. 2011;476:450–3.
19. Ferguson NM, Kien DT, Clapham H, Aguas R, Trung VT, Chau TN, et al.
Modeling the impact on virus transmission of Wolbachia-mediated blocking
of dengue virus infection of Aedes aegypti. Sci Transl Med. 2015;7:279ra37.
20. Yogyakarta Statistical Office (BPS). Population by Municipality, Special
Region of Yogyakarta. https://yogyakarta.bps.go.id/linkTabelStatis. Accessed
22 May 2017.
21. Ramadona AL, Lazuardi L, Hii YL, Holmner A, Kusnanto H, Rocklov J.
Prediction of dengue outbreaks based on disease surveillance and
meteorological data. PLoS One. 2016;11:e0152688.
22. Jewell NP, Dufault S, Cutcher Z, Simmons CP, Anders KL. Analysis of cluster
randomized test-negative designs: cluster-level methods. Biostatistics. 2018;
https://doi.org/10.1093/biostatistics/kxy005.
Anders et al. Trials  (2018) 19:302 Page 15 of 16
23. Anders KL, Cutcher Z, Kleinschmidt I, Donnelly C, Ferguson N, O'Neill SL, et
al. Cluster randomized test-negative design (CR-TND) trials: a novel and
efficient method to assess the efficacy of community level dengue
interventions. Am J Epidemiol. 2018. doi:10.1093/aje/kwy099.
24. Hayes RJ, Moulton LH. Cluster Randomized Trials. London: Chapman & Hall/
CRC Press; 2009.
25. Li F, Lokhnygina Y, Murray DM, Heagerty PJ, DeLong ER. An evaluation of
constrained randomization for the design and analysis of group-
randomized trials. Stat Med. 2016;35:1565–79.
26. Moulton LH. Covariate-based constrained randomization of group-
randomized trials. Clin Trials. 2004;1:297–305.
27. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al.
Evaluation of commercially available anti-dengue virus immunoglobulin M
tests. Emerg Infect Dis. 2009;15:436–40.
28. Guzman MG, Jaenisch T, Gaczkowski R, Ty Hang VT, Sekaran SD, Kroeger A,
et al. Multi-country evaluation of the sensitivity and specificity of two
commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl
Trop Dis 2010;4(8). pii:e811.
29. Small DS, Ten Have TR, Rosenbaum PR. Randomization inference in a
group-randomized trial of treatments for depression: Covariate adjustment,
noncompliance, and quantile effects. J Amer Statist Assoc. 2008;103:271–9.
30. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical sciences.
Behav Res Methods. 2007;39:175–91.
31. Haybittle JL. Repeated assessment of results in clinical trials of cancer
treatment. Br J Radiol. 1971;44:793–7.
32. World Health Organization. Mosquito (vector) control emergency response
and preparedness for Zika virus. 2016. http://www.who.int/neglected_
diseases/news/mosquito_vector_control_response/en/. Accessed 1 May
2017.
33. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for
measuring influenza vaccine effectiveness: a systematic review. Expert Rev
Vaccines. 2014;13:1571–91.
34. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al.
Methodologic issues regarding the use of three observational study designs
to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36:623–31.
35. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for
studies of the effectiveness of influenza vaccine. Vaccine. 2013;31:3104–9.
36. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-
negative study design for assessment of influenza vaccine effectiveness. Am
J Epidemiol. 2016;184:345–53.
37. Jackson ML, Nelson JC. The test-negative design for estimating influenza
vaccine effectiveness. Vaccine. 2013;31:2165–8.
38. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative
design: validity, accuracy and precision of vaccine efficacy estimates
compared to the gold standard of randomised placebo-controlled clinical
trials. Euro Surveill. 2013;18(37).
39. Bhoomiboonchoo P, Gibbons RV, Huang A, Yoon IK, Buddhari D, Nisalak A,
et al. The spatial dynamics of dengue virus in Kamphaeng Phet, Thailand.
PLoS Negl Trop Dis. 2014;8:e3138.
40. Teurlai M, Huy R, Cazelles B, Duboz R, Baehr C, Vong S. Can human
movements explain heterogeneous propagation of dengue fever in
Cambodia? PLoS Negl Trop Dis. 2012;6:e1957.
41. Restrepo AC, Baker P, Clements AC. National spatial and temporal patterns
of notified dengue cases, Colombia 2007-2010. Tropical Med Int Health.
2014;19:863–71.
42. Endy TP, Nisalak A, Chunsuttiwat S, Libraty DH, Green S, Rothman AL, et al.
Spatial and temporal circulation of dengue virus serotypes: a prospective
study of primary school children in Kamphaeng Phet, Thailand. Am J
Epidemiol. 2002;156:52–9.
43. Yoon IK, Getis A, Aldstadt J, Rothman AL, Tannitisupawong D, Koenraadt CJ,
et al. Fine scale spatiotemporal clustering of dengue virus transmission in
children and Aedes aegypti in rural Thai villages. PLoS Negl Trop Dis. 2012;6:
e1730.
44. Mammen MP, Pimgate C, Koenraadt CJ, Rothman AL, Aldstadt J, Nisalak A,
et al. Spatial and temporal clustering of dengue virus transmission in Thai
villages. PLoS Med. 2008;5:e205.
45. Cummings DA, Irizarry RA, Huang NE, Endy TP, Nisalak A, Ungchusak K, et al.
Travelling waves in the occurrence of dengue haemorrhagic fever in
Thailand. Nature. 2004;427:344–7.
46. Salje H, Lessler J, Endy TP, Curriero FC, Gibbons RV, Nisalak A, et al. Revealing the
microscale spatial signature of dengue transmission and immunity in an urban
population. Proc Natl Acad Sci U S A. 2012;109:9535–8.
47. Haber M, An Q, Foppa IM, Shay DK, Ferdinands JM, Orenstein WA. A
probability model for evaluating the bias and precision of influenza vaccine
effectiveness estimates from case-control studies. Epidemiol Infect. 2015;143:
1417–26.
Anders et al. Trials  (2018) 19:302 Page 16 of 16
